The higher the bleeding risk, the greater the benefit of radial access in terms of mortality

Original title: Baseline bleeding risk and arterial access site practice in relation to procedural outcomes after percutaneous coronary intervention. Presenter: Mamas A. Mamas et al. J Am Coll Cardiol. 2014;64:1554-1564.

The transradial approach has been associated with reduced access site related bleeding complications as well as a reduced mortality in the context of PCI. It seems reasonable to assume that baseline bleeding risk could also influence the benefit associated to the transradial approach, but it has not yet been established.

This trial studied the relationship between baseline bleeding risk, the transradial approach and post PCI events of all patients included in the British Cardiovascular Intervention Society database.

Baseline bleeding risk was calculated with the modified Mehran score in 348689 patients undergoing PCI between the years2006 and 2011. Patients were divided according to score in 4 categories of risk (low <10, moderate 10-14, high 15-19 and very high ≥20). The impact of baseline risk was analyzed on mortality at 30 days, according to access site.

Radial access was associated to a reduction of 35% mortality at 30 days (OR 0.65, IC 95% 0.59 to 0.72; p < 0.0001) and this reduction was associated to baseline bleeding risk (for those with

Conclusion

The transradial approach was independently associated to a reduction of mortality at 30 days and the magnitude of this effect was associated to bleeding risk. PCI patients with higher risk of bleeding are the ones that most benefit from the transradial approach.

Editorial Comment

In this study of the daily practice it was observed that 43% of patients with the lowest bleeding risk received the radial approach and, unexpectedly, only 40% of patients with the highest bleeding risk saw the same benefit. Even though there is enough evidence to adopt the transradial approach in all patients, we should give special attention to those with higher risk of bleeding, risk that should be calculated prior to intervention and should be known by the operator for him to make an informed decision on the most appropriate access site.

SOLACI

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure, peripheral edema, ascites, kidney failure and cardiohepatic...

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...